Anticoagulants
Arthroplasty, Replacement, Hip
Drug Overdose
Pulmonary Embolism
Venous Thrombosis

Apixaban

Apixaban is a novel oral anticoagulant approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots. Later, in 2014, apixaban gained approval for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of blood clots (DVT and PE) in patients who have undergone knee or hip replacement surgery. The drug is also approved for reducing the risk of recurrent DVT and PE after initial therapy. This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, overdose management, and toxicity of apixaban, thereby providing clinicians with a robust understanding of apixaban for treating various conditions and facilitating informed decision-making. This activity emphasizes that premature apixaban discontinuation heightens thrombotic event risks, necessitating consideration of alternative anticoagulants. By addressing these significant topics, this activity aims to enhance the proficiency and competence of healthcare professionals in managing apixaban therapy, thereby leading to improved patient outcomes.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.